Search Results - "SHIRAI, Keisuke"

Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma by Afzal, Muhammad Zubair, Mercado, Rima R, Shirai, Keisuke

“…Metformin is one of the biguanides commonly used in patients with type II Diabetes Mellitus. Apart from its hypoglycemic properties, metformin also inhibits…”
Get full text

A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors by Britten, Carolyn D, Garrett-Mayer, Elizabeth, Chin, Steven H, Shirai, Keisuke, Ogretmen, Besim, Bentz, Tricia A, Brisendine, Alan, Anderton, Kate, Cusack, Susan L, Maines, Lynn W, Zhuang, Yan, Smith, Charles D, Thomas, Melanie B

“…Sphingosine kinases (SK1 and SK2) regulate tumor growth by generating the mitogenic and proinflammatory lipid sphingosine 1-phosphate (S1P). This phase I study…”
Get full text

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs by Kris, Mark G, Johnson, Bruce E, Berry, Lynne D, Kwiatkowski, David J, Iafrate, A. John, Wistuba, Ignacio I, Varella-Garcia, Marileila, Franklin, Wilbur A, Aronson, Samuel L, Su, Pei-Fang, Shyr, Yu, Camidge, D. Ross, Sequist, Lecia V, Glisson, Bonnie S, Khuri, Fadlo R, Garon, Edward B, Pao, William, Rudin, Charles, Schiller, Joan, Haura, Eric B, Socinski, Mark, Shirai, Keisuke, Chen, Heidi, Giaccone, Giuseppe, Ladanyi, Marc, Kugler, Kelly, Minna, John D, Bunn, Paul A

“…IMPORTANCE Targeting oncogenic drivers (genomic alterations critical to cancer development and maintenance) has transformed the care of patients with lung…”
Get full text

Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors by Afzal, Muhammad Z, Dragnev, Konstantin, Sarwar, Tayyaba, Shirai, Keisuke

“…To study the clinical benefits of concurrent metformin and immune checkpoint inhibitors (ICIs) in non-small-cell lung cancer patients. This is a retrospective…”
Get full text

Secondary hemophagocytic syndrome in adults: a case series of 18 patients in a single institution and a review of literature by Shabbir, Munira, Lucas, John, Lazarchick, John, Shirai, Keisuke

“…Hemophagocytic lymphohistiocytosis (HLH) is rare in adults and is usually fatal without treatment. We present a consecutive series of 18 adults with HLH…”
Get full text

Clinical influence of multiplex polymerase chain reaction routine uses in urgent pediatric admissions by Kuribayashi, Mutsuko, Otake, Shogo, Kamiyoshi, Naohiro, Naito, Sanae, Yamamoto, Yuko, Shirai, Keisuke, Fujisawa, Kai, Kasai, Masashi, Kugo, Masaaki

“…Background The coronavirus disease 2019 outbreak has prompted some hospitals to implement screening tests upon admission since 2020. FilmArray® Respiratory 2.1…”
Get full text

Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone by Afzal, Muhammad Zubair, Mabaera, Rodwell, Shirai, Keisuke

“…Uveal melanoma accounts for 85% of the ocular melanomas and has an increased risk of hematogenous spread, most commonly to the liver. After curative intent…”
Get full text

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden by Morrison, Carl, Pabla, Sarabjot, Conroy, Jeffrey M, Nesline, Mary K, Glenn, Sean T, Dressman, Devin, Papanicolau-Sengos, Antonios, Burgher, Blake, Andreas, Jonathan, Giamo, Vincent, Qin, Moachun, Wang, Yirong, Lenzo, Felicia L, Omilian, Angela, Bshara, Wiam, Zibelman, Matthew, Ghatalia, Pooja, Dragnev, Konstantin, Shirai, Keisuke, Madden, Katherine G, Tafe, Laura J, Shah, Neel, Kasuganti, Deepa, de la Cruz-Merino, Luis, Araujo, Isabel, Saenger, Yvonne, Bogardus, Margaret, Villalona-Calero, Miguel, Diaz, Zuanel, Day, Roger, Eisenberg, Marcia, Anderson, Steven M, Puzanov, Igor, Galluzzi, Lorenzo, Gardner, Mark, Ernstoff, Marc S

“…Immune checkpoint inhibitors (ICIs) have changed the clinical management of melanoma. However, not all patients respond, and current biomarkers including PD-L1…”
Get full text

Amelioration of Insulin Resistance by Whey Protein in a High-Fat Diet-Induced Pediatric Obesity Male Mouse Model by Matsuda, Kengo, Nagano, Nobuhiko, Nakazaki, Kimitaka, Katayama, Daichi, Tokunaga, Wataru, Okuda, Koh, Shimizu, Shoichi, Aoki, Ryoji, Fuwa, Kazumasa, Shirai, Keisuke, Fujioka, Kazumichi, Morioka, Ichiro

“…This study examined whey protein's impact on insulin resistance in a high-fat diet-induced pediatric obesity mouse model. Pregnant mice were fed high-fat…”
Get full text

Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients by Pabla, Sarabjot, Conroy, Jeffrey M, Nesline, Mary K, Glenn, Sean T, Papanicolau-Sengos, Antonios, Burgher, Blake, Hagen, Jacob, Giamo, Vincent, Andreas, Jonathan, Lenzo, Felicia L, Yirong, Wang, Dy, Grace K, Yau, Edwin, Early, Amy, Chen, Hongbin, Bshara, Wiam, Madden, Katherine G, Shirai, Keisuke, Dragnev, Konstantin, Tafe, Laura J, Marin, Daniele, Zhu, Jason, Clarke, Jeff, Labriola, Matthew, McCall, Shannon, Zhang, Tian, Zibelman, Matthew, Ghatalia, Pooja, Araujo-Fernandez, Isabel, Singavi, Arun, George, Ben, MacKinnon, Andrew Craig, Thompson, Jonathan, Singh, Rajbir, Jacob, Robin, Dressler, Lynn, Steciuk, Mark, Binns, Oliver, Kasuganti, Deepa, Shah, Neel, Ernstoff, Marc, Odunsi, Kunle, Kurzrock, Razelle, Gardner, Mark, Galluzzi, Lorenzo, Morrison, Carl

“…Resistance to immune checkpoint inhibitors (ICIs) has been linked to local immunosuppression independent of major ICI targets (e.g., PD-1). Clinical experience…”
Get full text

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors by Conroy, Jeffrey M, Pabla, Sarabjot, Nesline, Mary K, Glenn, Sean T, Papanicolau-Sengos, Antonios, Burgher, Blake, Andreas, Jonathan, Giamo, Vincent, Wang, Yirong, Lenzo, Felicia L, Bshara, Wiam, Khalil, Maya, Dy, Grace K, Madden, Katherine G, Shirai, Keisuke, Dragnev, Konstantin, Tafe, Laura J, Zhu, Jason, Labriola, Matthew, Marin, Daniele, McCall, Shannon J, Clarke, Jeffrey, George, Daniel J, Zhang, Tian, Zibelman, Matthew, Ghatalia, Pooja, Araujo-Fernandez, Isabel, de la Cruz-Merino, Luis, Singavi, Arun, George, Ben, MacKinnon, Alexander C, Thompson, Jonathan, Singh, Rajbir, Jacob, Robin, Kasuganti, Deepa, Shah, Neel, Day, Roger, Galluzzi, Lorenzo, Gardner, Mark, Morrison, Carl

“…PD-L1 immunohistochemistry (IHC) has been traditionally used for predicting clinical responses to immune checkpoint inhibitors (ICIs). However, there are at…”
Get full text

A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma by Hasanov, Merve, Rioth, Matthew J, Kendra, Kari, Hernandez-Aya, Leonel, Joseph, Richard W, Williamson, Stephen, Chandra, Sunandana, Shirai, Keisuke, Turner, Christopher D, Lewis, Karl, Crowley, Elizabeth, Moscow, Jeffrey, Carter, Brett, Patel, Sapna

“…Glembatumumab vedotin (CDX-011, GV) is a fully human Immunoglobulin G2 monoclonal antibody directed against glycoprotein NMB coupled via a peptide linker to…”
Get full text

Estimation of Assist Effects by Additional Permanent Magnets in Salient-Pole Synchronous Generators by Yamazaki, K., Nishioka, K., Shima, K., Fukami, T., Shirai, K.

“…The characteristic improvements of salient-pole synchronous generators by inserting additional permanent magnets are investigated from both results of…”
Get full text

Depletion of conventional CD4 + T cells is required for robust priming and dissemination of tumor antigen-specific CD8 + T cells in the setting of anti-CD4 therapy by Ramirez, Delaney E, Dragnev, Christo P C, Searles, Tyler G, Spicer, Nathaniel, Chen, Tiffany, Lines, J Louise, Hawkes, Aaron R, Davis, Wilson L, Mohamed, Asmaa, Shirai, Keisuke, Phillips, Joseph D, Rosato, Pamela C, Huang, Yina H, Turk, Mary Jo

“…Overcoming immune suppression is a major barrier to eliciting potent CD8+ T cell responses against cancer. Treatment with anti-CD4 monoclonal antibody is an…”
Get full text

47 Baseline blood DNA methylation-based immune profiles and tumor mutational burden predict survival outcomes in anti-PD-1 treated head and neck cancer patient by Zhang, Ze, Sehgal, Kartik, Shirai, Keisuke, Butler, Rondi, Wiencke, John, Koestler, Devin, Ramush, Geat, Lee, Min Kyung, Molinaro, Annette, Stolrow, Hannah, Salas, Lucas A, Haddad, Robert, Kelsey, Karl, Christensen, Brock

“…BackgroundImmune checkpoint inhibitors (ICIs) are approved to treat patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). However,…”
Get full text

Clinical Genotyping of Non–Small Cell Lung Cancers Using Targeted Next-Generation Sequencing: Utility of Identifying Rare and Co-mutations in Oncogenic Driver Genes by Tafe, Laura J, Pierce, Kirsten J, Peterson, Jason D, de Abreu, Francine, Memoli, Vincent A, Black, Candice C, Pettus, Jason R, Marotti, Jonathan D, Gutmann, Edward J, Liu, Xiaoying, Shirai, Keisuke, Dragnev, Konstantin H, Amos, Christopher I, Tsongalis, Gregory J

“…Abstract Detection of somatic mutations in non–small cell lung cancers (NSCLCs), especially adenocarcinomas, is important for directing patient care when…”
Get full text

Methylation cytometric pretreatment blood immune profiles with tumor mutation burden as prognostic indicators for survival outcomes in head and neck cancer patients on anti-PD-1 therapy by Zhang, Ze, Sehgal, Kartik, Shirai, Keisuke, Butler, Rondi A., Wiencke, John K., Koestler, Devin C., Ramush, Geat, Lee, Min Kyung, Molinaro, Annette M., Stolrow, Hannah G., Birnbaum, Ariel, Salas, Lucas A., Haddad, Robert I., Kelsey, Karl T., Christensen, Brock C.

“…Tissue biomarkers for immune checkpoint inhibitor (ICI) response are limited by tumor sample heterogeneity and availability. This study identifies clinically…”
Get full text

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0 by Pavlick, Anna C, Ariyan, Charlotte E, Buchbinder, Elizabeth I, Davar, Diwakar, Gibney, Geoffrey T, Hamid, Omid, Hieken, Tina J, Izar, Benjamin, Johnson, Douglas B, Kulkarni, Rajan P, Luke, Jason J, Mitchell, Tara C, Mooradian, Meghan J, Rubin, Krista M, Salama, April KS, Shirai, Keisuke, Taube, Janis M, Tawbi, Hussein A, Tolley, J Keith, Valdueza, Caressa, Weiss, Sarah A, Wong, Michael K, Sullivan, Ryan J

“…Since the first approval for immune checkpoint inhibitors (ICIs) for the treatment of cutaneous melanoma more than a decade ago, immunotherapy has completely…”
Get full text

Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients by Zhang, Tian, Pabla, Sarabjot, Lenzo, Felicia L., Conroy, Jeffrey M., Nesline, Mary K., Glenn, Sean T., Papanicolau-Sengos, Antonios, Burgher, Blake, Giamo, Vincent, Andreas, Jonathan, Wang, Yirong, Bshara, Wiam, Madden, Katherine G., Shirai, Keisuke, Dragnev, Konstantin, Tafe, Laura J., Gupta, Rajan, Zhu, Jason, Labriola, Matthew, McCall, Shannon, George, Daniel J., Ghatalia, Pooja, Dayyani, Farshid, Edwards, Robert, Park, Michelle S, Singh, Rajbir, Jacob, Robin, George, Saby, Xu, Bo, Zibelman, Matthew, Kurzrock, Razelle, Morrison, Carl

“…Biomarkers predicting immunotherapy response in metastatic renal cell cancer (mRCC) are lacking. PD-L1 immunohistochemistry is a complementary diagnostic for…”
Get full text

Treatment Considerations for Patients with Unresectable Metastatic Melanoma Who Develop Pembrolizumab-Induced Guillain-Barré Toxicity: A Case Report by Muralikrishnan, Sivraj, Ronan, Lara K., Coker, Shodeinde, Rauschkolb, Paula K., Shirai, Keisuke

“…Immunotherapy has improved outcomes in many malignancies, most notably in melanoma, lung cancer, and bladder cancer. Understanding the side effects associated…”
Get full text